- AUD/USD edges higher after posting biggest daily jump in four months on Monday.
- Market sentiment improved on vaccine news, easy money hopes.
- Downbeat PMIs push back expectations of tapering, favored equities and gold.
- Consolidation of last week’s heavy losses can continue amid a light calendar, risk catalysts are crucial.
AUD/USD keeps the week-start bounce off yearly low near 0.7210 during the early Tuesday morning in Asia. The Aussie pair dropped the most in 11 months the previous week before marking the heaviest daily rise since April the previous day. While the coronavirus woes could be considered as a major drawback, the latest recovery in equities and gold, backed by a downbeat US dollar, favor the pair buyers.
Australia’s daily coronavirus cases remain near the record top but the latest news on the vaccine and downbeat PMI’s favor the AUD/USD buyers. That said, the Oz nation registered another 900+ infections on Monday but New South Wales (NSW), the most infected state, registers the fastest vaccination pace in the world and is keeping the optimists hopeful.
On the same line, the US Food and Drug Administration (FDA) approved Moderna–BioNTech covid vaccine for use over 16 years and above, which in turn offered another weapon to battle the pandemic.
Elsewhere, the preliminary readings of August month’s activity numbers from the US, Europe, the UK and Australia all suggest a bit of softening despite rejecting the contraction. The same helps the US Federal Reserve (Fed) and its friends on the line to reject challenges for their easy-money policies.
These catalysts helped Wall Street to post a happy start to the week while gold also regains $1,800 level due to the risk-on mood. It’s worth noting that the US Dollar Index (DXY) and the US 10-year Treasury yields were softer by the end of Monday’s trading session.
Looking forward, a lack of major data/events may keep AUD/USD traders at the mercy of qualitative catalysts for immediate direction. Among them, news on the coronavirus, vaccine and central banks will be the key to follow.
AUD/USD bounces off nine-month low amid oversold RSI conditions, suggesting further recovery towards October 2020 peak surrounding 0.7140-45. However, bulls are less likely to be convinced until witnessing a daily closing beyond July’s low of 0.7288. Alternatively, June 2020 high near 0.7065 can entertain sellers during the pair’s fresh downside.
Additional important levels
|Today last price||0.7212|
|Today Daily Change||0.0082|
|Today Daily Change %||1.15%|
|Today daily open||0.713|
|Previous Daily High||0.7157|
|Previous Daily Low||0.7106|
|Previous Weekly High||0.7373|
|Previous Weekly Low||0.7106|
|Previous Monthly High||0.7599|
|Previous Monthly Low||0.7288|
|Daily Fibonacci 38.2%||0.7125|
|Daily Fibonacci 61.8%||0.7137|
|Daily Pivot Point S1||0.7105|
|Daily Pivot Point S2||0.7079|
|Daily Pivot Point S3||0.7053|
|Daily Pivot Point R1||0.7156|
|Daily Pivot Point R2||0.7182|
|Daily Pivot Point R3||0.7208|
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers. The author will not be held responsible for information that is found at the end of links posted on this page.
If not otherwise explicitly mentioned in the body of the article, at the time of writing, the author has no position in any stock mentioned in this article and no business relationship with any company mentioned. The author has not received compensation for writing this article, other than from FXStreet.
FXStreet and the author do not provide personalized recommendations. The author makes no representations as to the accuracy, completeness, or suitability of this information. FXStreet and the author will not be liable for any errors, omissions or any losses, injuries or damages arising from this information and its display or use. Errors and omissions excepted.
The author and FXStreet are not registered investment advisors and nothing in this article is intended to be investment advice.